Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, today announced the launch of GELICIOUS!(TM) and GELMEG3(TM), the first and only Omega 3 supplements in a tasty gel format, specifically designed for those among us who do not like to and/or cannot swallow pills. Both GELICIOUS!(TM) for kids and GELMEG3(TM) for adults contain Health Canada approved key levels of DHA (docosahexanoic acid) and EPA (eicosapentaenoic acid) that previously could have proved difficult for non-fish eaters to ensure they consume as part of their normal daily nutritional intake.
With these branded products Paladin is excited to extend its innovative approach from prescription and OTC products into the realm of nutritional supplements via the BioEnvelop(R) division. Both Gelicious!(TM) and GelMeg3(TM) are not only unique given their creamy orange texture, but both brands are truly satisfying a unique need in the marketplace as research indicates that at least 40% of adults have issues with swallowing pills. For the first time in Canada - a convenient Omega 3 daily supplement that tastes great at room temperature or cold.
About Omega 3
The Omega 3 fatty acid is a form of highly polyunsaturated fat, one of the 'good' fats not naturally manufactured by the human body, is clinically proven to contribute to good health overall, with specific links to brain function, cognitive skills and heart health. Defined as 'essential' to good human health, the two key long chain forms of Omega 3, DHA and EPA, are primarily derived from cold water fish and frequently recommended as supplements to diets low in fish consumption.
About GELICIOUS!(TM) for Kids
Gelicious!(TM) is specifically formulated to help support the development of the brain, eyes and nerves among school-aged children, 4-17, in addition to helping to support cognitive skills such as communication and reasoning. Each dose delivers a total of 650mg of DHA (229mg) and EPA (429mg) in a fun tube-like gel pack bursting with orange flavour, ready to be sucked on.
For more information, please visit www.geliciousgels.com.
About GELMEG3(TM) for Adults
GelMeg3(TM) contains 1000mg of DHA (343mg) and EPA (658mg), recognized by Health Canada as contributing to the maintenance of good cardiovascular health overall and specifically as an aid in lowering serum triglycerides. Although not as well known as cholesterol, the other lipid/fat present in our blood, high triglyceride levels are clinically proven to be associated with an increased risk of cardiovascular disease.
For more information, please visit www.gelmeg3.com.
Each box of GELICIOUS!(TM) And GELMEG3(TM) contain a two-week supply of 14 gel packs and are available at select Shoppers Drug Mart and Pharmaprix stores across Canada.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies.
For more information, please visit the Company's web site at www.paladinlabs.com.
Founded in 1998, BioEnvelop(R) designs and manufactures state-of-the-art Delivery Systems of Active Ingredients in both film and gel formats that have wide applications in the Medical & Dental, Health & Wellness and Oral Care industries. BioEnvelop(R) has a license to manufacture under the Natural Health Products (NHP) certification program of Canada. BioEnvelop(R) continues to offer many new opportunities for Nutraceutical companies to change from a current product format into a new delivery system or just begin with an entirely new product application. In either case, BioEnvelop(R) has the passion, the resources and the complete focus to execute the introduction of a new product delivery concept to the marketplace and is constantly looking for new technologies and partnerships.
For more information, please visit www.bioenvelop.com.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2008. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.